Fintel reports that on December 6, 2023, Jefferies upgraded their outlook for Arvinas (NASDAQ:ARVN) from Hold to Buy .
Analyst Price Forecast Suggests 137.98% Upside
As of November 27, 2023, the average one-year price target for Arvinas is 55.14. The forecasts range from a low of 20.20 to a high of $99.75. The average price target represents an increase of 137.98% from its latest reported closing price of 23.17.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Arvinas is 120MM, a decrease of 24.44%. The projected annual non-GAAP EPS is -6.20.
What is the Fund Sentiment?
There are 418 funds or institutions reporting positions in Arvinas. This is an increase of 12 owner(s) or 2.96% in the last quarter. Average portfolio weight of all funds dedicated to ARVN is 0.21%, an increase of 9.68%. Total shares owned by institutions increased in the last three months by 7.15% to 53,160K shares. 
The put/call ratio of ARVN is 0.38, indicating a bullish outlook.
What are Other Shareholders Doing?
EcoR1 Capital holds 5,467K shares representing 9.94% ownership of the company. In it's prior filing, the firm reported owning 4,018K shares, representing an increase of 26.51%. The firm increased its portfolio allocation in ARVN by 48.23% over the last quarter.
Price T Rowe Associates holds 2,689K shares representing 4.89% ownership of the company. In it's prior filing, the firm reported owning 2,694K shares, representing a decrease of 0.20%. The firm decreased its portfolio allocation in ARVN by 16.95% over the last quarter.
Avidity Partners Management holds 2,615K shares representing 4.75% ownership of the company. In it's prior filing, the firm reported owning 2,773K shares, representing a decrease of 6.05%. The firm decreased its portfolio allocation in ARVN by 13.97% over the last quarter.
Bellevue Group holds 2,125K shares representing 3.86% ownership of the company. In it's prior filing, the firm reported owning 2,127K shares, representing a decrease of 0.08%. The firm decreased its portfolio allocation in ARVN by 19.28% over the last quarter.
ArrowMark Colorado Holdings holds 2,087K shares representing 3.79% ownership of the company. In it's prior filing, the firm reported owning 1,802K shares, representing an increase of 13.65%. The firm increased its portfolio allocation in ARVN by 1.61% over the last quarter.
Arvinas Background Information
(This description is provided by the company.)
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and "undruggable" targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
